Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition

SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in Europe. Beyond their initial applications in rare tumors, these small molecules are also being studied as monotherapies and as part of combinations treatments for certain cancers. The post Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition appeared…

Read More

Value-Based Care Gets Real

The mandatory CMS TEAM program begins next year. Are you ready? As hospitals consider their options for addressing the mandate, here are some actions to consider. The post Value-Based Care Gets Real appeared first on MedCity News.

Read More

Cuando los abuelos ya no te reconocen

Ocurrió hace más de una década, pero el momento permanece en su memoria. Sara Stewart conversaba con su madre, Barbara Cole, entonces de 86 años, en el comedor de su casa de Bar Harbor, en Maine. Stewart, abogada tenía en ese momento 59 años y estaba haciendo una de sus largas visitas desde fuera del…

Read More